Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pyxis Oncology, Inc.PYXS · Entity 5986 | Chief Medical Officer | December 29, 2023 | December 29, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pyxis Oncology, Inc.
Report date December 29, 2023 · Filed December 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2033-12-29 | Direct | 443,514 |
Reported balance
After 2023-12-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-12-29 · Grant · Acquired 443,514 · Balance 443,514 F1: The shares subject to this option will vest over four years, with 25% vesting on November 27, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2033-12-29 | Direct | 110,878 |
Reported balance
After 2023-12-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-12-29 · Grant · Acquired 110,878 · Balance 110,878 F2: The shares subject to this option will vest upon the achievement of certain clinical milestones related to data disclosure for PYX-201. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option will vest over four years, with 25% vesting on November 27, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates.
F2: The shares subject to this option will vest upon the achievement of certain clinical milestones related to data disclosure for PYX-201.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2023 Filed Dec 29, 2023 16:33 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 110,878 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001209191-23-060006 · doc4.xml · derivative · entry 2 Kobayashi Ken · CIK 0002003383 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,878 Underlying: Common Stock · 110,878 shares Expires 2033-12-29 F2 · derivative.exercise_date: The shares subject to this option will vest upon the achievement of certain clinical milestones related to data disclosure for PYX-201. Read SEC document |
| December 29, 2023 Filed Dec 29, 2023 16:33 UTC | Pyxis Oncology, Inc. PYXS · Entity 5986 | GrantStock Option (Right to Buy) · Derivative | 443,514 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0001209191-23-060006 · doc4.xml · derivative · entry 1 Kobayashi Ken · CIK 0002003383 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 443,514 Underlying: Common Stock · 443,514 shares Expires 2033-12-29 F1 · derivative.exercise_date: The shares subject to this option will vest over four years, with 25% vesting on November 27, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.